Antibodies to watch in 2026.

Historically, monoclonal antibodies were developed by companies based in the US or Europe, but analysis of product origins shows a notable trend toward development by companies headquartered outside these regions, particularly in China ( Figure 1 ).

also in 2,380 other papers

Our data also show a clear trend toward first marketing application submissions and approvals in China, which was the case for ~60% of the molecules we included in these two categories.

also in 19,460 other papers